Barclays
DSGN icon

Barclays’s Design Therapeutics DSGN Stock Holding History

Barclays’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$594K Sell
55,790
-31,270
-36% -$316K ﹤0.01% 3083
2025
Q4 		$817K Sell
87,060
-1,116
-1% -$8.74K ﹤0.01% 3570
2025
Q3 		$664K Sell
88,176
-21,360
-20% -$107K ﹤0.01% 3625
2025
Q2 		$369K Buy
109,536
+25,530
+30% +$95.5K ﹤0.01% 3928
2025
Q1 		$324K Sell
84,006
-19,565
-19% -$93.3K ﹤0.01% 3784
2024
Q4 		$639K Buy
103,571
+6,936
+7% +$40.1K ﹤0.01% 3671
2024
Q3 		$520K Buy
96,635
+24,602
+34% +$116K ﹤0.01% 3752
2024
Q2 		$241K Sell
72,033
-16,875
-19% -$65.8K ﹤0.01% 3476
2024
Q1 		$358K Sell
88,908
-22,046
-20% -$58.9K ﹤0.01% 3791
2023
Q4 		$294K Buy
110,954
+39,276
+55% +$90K ﹤0.01% 4224
2023
Q3 		$169K Buy
71,678
+55,858
+353% +$261K ﹤0.01% 3376
2023
Q2 		$99.7K Sell
15,820
-1,397
-8% -$8.55K ﹤0.01% 3566
2023
Q1 		$99.3K Sell
17,217
-113,782
-87% -$851K ﹤0.01% 4184
2022
Q4 		$1.34M Buy
130,999
+109,401
+507% +$1.48M ﹤0.01% 2565
2022
Q3 		$361K Sell
21,598
-183,967
-89% -$3.66M ﹤0.01% 2872
2022
Q2 		$2.88M Sell
205,565
-20,946
-9% -$283K ﹤0.01% 1626
2022
Q1 		$3.66M Buy
+226,511
New +$3.47M ﹤0.01% 1421

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's DSGN Position: Q1 2026 in Review

Barclays reduced its Design Therapeutics (DSGN) stake by 36% in Q1 2026, selling an estimated $316K and leaving 55,790 shares worth $594K. The position accounts for ﹤0.01% of the portfolio, ranked #3083.

Barclays first reported a position in DSGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $3.66M in Q1 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Barclays held 55,790 shares of Design Therapeutics worth $594K as of Q1 2026.
  • Barclays sold 31,270 Design Therapeutics shares in Q1 2026, an estimated $316K.
  • Design Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3083 holding.
  • Barclays first reported a position in Design Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Design Therapeutics position peaked at $3.66M in Q1 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.